These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 23564814)

  • 1. HE4 tissue expression in borderline ovarian tumors: a pilot study by the tumorbank ovarian cancer network.
    Nassir M; Darb-Esfahani S; Richter R; Chekerov R; Hall C; Muallem MZ; Denkert C; Stamatian F; Fotopoulou C; Sehouli J; Braicu EI
    Anticancer Res; 2013 Apr; 33(4):1673-7. PubMed ID: 23564814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.
    Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M
    Int J Oncol; 2002 Aug; 21(2):315-20. PubMed ID: 12118327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.
    Borgoño CA; Kishi T; Scorilas A; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP
    Clin Cancer Res; 2006 Mar; 12(5):1487-93. PubMed ID: 16533772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biparametric Magnetic Resonance Imaging as an Adjunct to CA125 and HE4 to Improve Characterization of Large Ovarian Masses.
    Manganaro L; Anastasi E; Porpora MG; Vinci V; Saldari M; Bernardo S; Ballesio L; Sollazzo P; Pecorella I; Recchia N; Stracci F; Panici PB; Angeloni A; Catalano C; Scialpi M
    Anticancer Res; 2015 Nov; 35(11):6341-51. PubMed ID: 26504074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B7-H4 overexpression in ovarian tumors.
    Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
    Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
    Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human telomerase reverse transcriptase (hTERT) expression in borderline ovarian tumors: an immunohistochemical study.
    Tantbirojn P; Triratanachat S; Trivijitsilp P; Niruthisard S
    J Med Assoc Thai; 2009 Mar; 92(3):308-14. PubMed ID: 19301721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and prognostic significance of the oncogenic K2P potassium channel KCNK9 (TASK-3) in ovarian carcinoma.
    Innamaa A; Jackson L; Asher V; Van Shalkwyk G; Warren A; Hay D; Bali A; Sowter H; Khan R
    Anticancer Res; 2013 Apr; 33(4):1401-8. PubMed ID: 23564779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
    Lin CK; Chao TK; Yu CP; Yu MH; Jin JS
    APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome.
    Bagnoli M; Ambrogi F; Pilotti S; Alberti P; Ditto A; Barbareschi M; Galligioni E; Biganzoli E; Canevari S; Mezzanzanica D
    Endocr Relat Cancer; 2009 Jun; 16(2):443-53. PubMed ID: 19321593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pattern of tissue expression of CA-125 and HE4 in primary epithelial ovarian tumours and correlation with serum CA-125 levels.
    Devan SM; Pailoor J; Sthaneshwar P; Narayanan V
    Asian Pac J Cancer Prev; 2013; 14(8):4545-8. PubMed ID: 24083699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinicopathological significance of Bax and Bcl-2 protein expression with tumor infiltrating lymphocytes in ovarian carcinoma.
    Yigit S; Demir L; Tarhan MO; Cabuk FK; Ellidokuz H; Erten C; Somali I; Dirican A; Cakalagaoglu F
    Neoplasma; 2012; 59(5):475-85. PubMed ID: 22668011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer.
    Yin M; Li C; Li X; Lou G; Miao B; Liu X; Meng F; Zhang H; Chen X; Sun M; Ling Q; Zhou R
    J Surg Oncol; 2011 Jul; 104(1):29-36. PubMed ID: 21416470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of folate receptor alpha in ovarian epithelial tumors].
    Shen DH; Xie JL; Zhang YL; Wang Y
    Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):747-51. PubMed ID: 21215165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma.
    Davidson B; Alejandro E; Flørenes VA; Goderstad JM; Risberg B; Kristensen GB; Trope CG; Kohn EC
    Cancer; 2004 May; 100(10):2139-47. PubMed ID: 15139056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.
    Yoshida H; Sumi T; Zhi X; Yasui T; Honda K; Ishiko O
    Anticancer Res; 2011 Apr; 31(4):1271-7. PubMed ID: 21508375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
    Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
    Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.